$UNH — AVOID 📊 | 6 MONTHS THESIS

$UNH — AVOID 📊 | 6 MONTHS THESIS 🎯 Q1 2026 | Rev $111.7B | EPS $7.23 vs $6.60 🟢 | Margin 8.1% 💡 Market consensus appears to expect continued steady growth, but the quant rank of 0th percentile and a reward/risk of 0.2:1 suggest the upside is limited and downside risk is elevated. The earnings surprise may not be sustained, and the stock is vulnerable to mean reversion in valuation or a guidance reset. 📉 Reward/risk: 0.2:1 🏢 Business Quality: 8/10 - UnitedHealth Group is a dominant, diversified healthcare player with strong competitive advantages, defensive revenue streams, and a track record of execution. 📊 Valuation: fair — P/E 30.8x is near its 47th percentile historically (range 23.1–39.5x, median 34.8x), not deeply discounted. 🔮 Catalyst: Q2 2026 earnings report (expected mid-July 2026) 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/UNH0624

🎯 Q1 2026 | Rev $111.7B | EPS $7.23 vs $6.60 🟢 | Margin 8.1%